Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma
RNA-seq (gene expression) · mouse · 31 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 31 samples: 31 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Regorafenib enhances M1/M2 macrophage polarization by inhibiting the secretion of plasminogen activator inhibitor-1 in head and neck squamous cell carcinomaLife sciences · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE248155_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1041830 and SRA study SRP472604. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 15 samples read as cases, 3 as controls.
How we read this: Read from 31 sample titles: 31 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7906479 HNSCC mouse models with treatment of vehicle (#1)
- GSM7906480 HNSCC mouse models with treatment of vehicle (#2)
- GSM7906481 HNSCC mouse models with treatment of vehicle (#3)
- GSM7906482 HNSCC mouse models with treatment of anti-PD1 (#1)
- GSM7906483 HNSCC mouse models with treatment of anti-PD1 (#2)
- GSM7906484 HNSCC mouse models with treatment of anti-PD1 (#3)
- GSM7906485 HNSCC mouse models with treatment of regorafenib (#1)
- GSM7906486 HNSCC mouse models with treatment of regorafenib (#2)
- GSM7906487 HNSCC mouse models with treatment of regorafenib (#3)
- GSM7906488 HNSCC mouse models with treatment of regorafenib + anti-PD1 (#1)
- GSM7906489 HNSCC mouse models with treatment of regorafenib + anti-PD1 (#2)
- GSM7906490 HNSCC mouse models with treatment of regorafenib + anti-PD1 (#3)
- GSM7906491 4NQO-induced oral cancer models with treatment of anti-CD40 agonist (#1)
- GSM7906492 4NQO-induced oral cancer models with treatment of anti-CD40 agonist (#2)
- GSM7906493 4NQO-induced oral cancer models with treatment of anti-CD40 agonist (#3)
- GSM7906494 4NQO-induced oral cancer models with treatment of vehicle control (#1)
- GSM7906495 4NQO-induced oral cancer models with treatment of vehicle control (#2)
- GSM7906496 4NQO-induced oral cancer models with treatment of vehicle control (#3)
- GSM7906497 4NQO-induced oral cancer models with treatment of vehicle control (#4)
- GSM7906498 4NQO-induced oral cancer models with treatment of anti-PD1 (#1)
- GSM7906499 4NQO-induced oral cancer models with treatment of anti-PD1 (#2)
- GSM7906500 4NQO-induced oral cancer models with treatment of anti-PD1 (#3)
- GSM7906501 4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#1)
- GSM7906502 4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#2)
- GSM7906503 4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#3)
- GSM7906504 4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#4)
- GSM7906505 4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#5)
- GSM7906506 4NQO-induced oral cancer models with treatment of regorafenib (#1)
- GSM7906507 4NQO-induced oral cancer models with treatment of regorafenib (#2)
- GSM7906508 4NQO-induced oral cancer models with treatment of regorafenib (#3)
- GSM7906509 4NQO-induced oral cancer models with treatment of regorafenib (#4)
- GSE248154 Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [4NQO_model] 19 samples shares anti-cd40, anti-pd1, regorafenib, squamous, agonist, head, neck
- GSE248153 Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [HNSCC_model] 12 samples shares anti-cd40, anti-pd1, regorafenib, squamous, agonist, head, neck
- GSE299686 Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma [bulk RNA-seq] 178 samples shares squamous, head, neck
- GSE299683 Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma [scRNA-seq] 125 samples shares squamous, head, neck
- GSE273232 Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse models. 8 samples shares squamous, head, neck
- GSE335338 EphA4 Mediates Pro- and Anti- Tumoral Effects Through Upstream Negative Regulation of AKT in Head and Neck Squamous Cell Carcinoma- The effect of EphA4 knockout on RNA expression in HNSCC cell line. 6 samples shares squamous, head, neck
- GSE228678 Glutamine inhibition combined with CD47 blockade enhances radiotherapy-induced ferroptosis in head and neck squamous cell carcinoma [RNA-Seq] 6 samples shares squamous, head, neck
- GSE297487 Impact of AIM2 on Head and Neck Squamous Cell Carcinoma Development 6 samples shares squamous, head, neck
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.